ChemoCentryx Inc (NASDAQ:CCXI) Major Shareholder Sells $4,627,670.96 in Stock

ChemoCentryx Inc (NASDAQ:CCXI) major shareholder (International) Ltd Vifor sold 88,012 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $52.58, for a total value of $4,627,670.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

(International) Ltd Vifor also recently made the following trade(s):

  • On Monday, July 27th, (International) Ltd Vifor sold 34,236 shares of ChemoCentryx stock. The stock was sold at an average price of $53.32, for a total value of $1,825,463.52.
  • On Wednesday, July 22nd, (International) Ltd Vifor sold 72,469 shares of ChemoCentryx stock. The stock was sold at an average price of $55.58, for a total value of $4,027,827.02.
  • On Friday, July 24th, (International) Ltd Vifor sold 133,074 shares of ChemoCentryx stock. The stock was sold at an average price of $54.62, for a total value of $7,268,501.88.
  • On Monday, July 20th, (International) Ltd Vifor sold 54,598 shares of ChemoCentryx stock. The stock was sold at an average price of $56.03, for a total value of $3,059,125.94.
  • On Friday, July 17th, (International) Ltd Vifor sold 47,890 shares of ChemoCentryx stock. The stock was sold at an average price of $55.86, for a total value of $2,675,135.40.
  • On Wednesday, July 15th, (International) Ltd Vifor sold 86,298 shares of ChemoCentryx stock. The stock was sold at an average price of $59.22, for a total value of $5,110,567.56.
  • On Monday, July 13th, (International) Ltd Vifor sold 100,000 shares of ChemoCentryx stock. The stock was sold at an average price of $58.15, for a total value of $5,815,000.00.
  • On Friday, July 10th, (International) Ltd Vifor sold 45,844 shares of ChemoCentryx stock. The stock was sold at an average price of $59.92, for a total value of $2,746,972.48.
  • On Wednesday, July 8th, (International) Ltd Vifor sold 100,000 shares of ChemoCentryx stock. The stock was sold at an average price of $59.95, for a total value of $5,995,000.00.
  • On Monday, July 6th, (International) Ltd Vifor sold 86,690 shares of ChemoCentryx stock. The stock was sold at an average price of $58.44, for a total value of $5,066,163.60.

Shares of ChemoCentryx stock opened at $52.71 on Friday. The stock’s 50-day simple moving average is $57.54 and its 200-day simple moving average is $50.31. ChemoCentryx Inc has a 52 week low of $6.16 and a 52 week high of $65.43. The company has a market capitalization of $3.26 billion, a price-to-earnings ratio of -48.36 and a beta of 2.04. The company has a quick ratio of 3.22, a current ratio of 3.22 and a debt-to-equity ratio of 0.40.

ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.05). The business had revenue of $6.01 million during the quarter, compared to analysts’ expectations of $8.90 million. ChemoCentryx had a negative net margin of 192.93% and a negative return on equity of 100.55%. On average, equities analysts expect that ChemoCentryx Inc will post -1.39 earnings per share for the current year.

Several analysts recently commented on CCXI shares. ValuEngine lowered ChemoCentryx from a “buy” rating to a “hold” rating in a report on Thursday, July 2nd. JPMorgan Chase & Co. cut their price target on ChemoCentryx from $64.00 to $61.00 and set an “overweight” rating for the company in a report on Wednesday. BTIG Research started coverage on ChemoCentryx in a report on Tuesday, June 16th. They set a “buy” rating and a $70.00 price target for the company. BidaskClub lowered ChemoCentryx from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Finally, Piper Sandler boosted their price target on ChemoCentryx from $54.00 to $70.00 and gave the company an “overweight” rating in a report on Monday, May 18th. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $68.70.

Several large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its position in shares of ChemoCentryx by 2.5% in the first quarter. JPMorgan Chase & Co. now owns 13,435 shares of the biopharmaceutical company’s stock worth $540,000 after buying an additional 330 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of ChemoCentryx by 3.4% in the first quarter. Principal Financial Group Inc. now owns 14,223 shares of the biopharmaceutical company’s stock worth $571,000 after buying an additional 468 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its position in shares of ChemoCentryx by 3.1% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 15,685 shares of the biopharmaceutical company’s stock worth $630,000 after buying an additional 470 shares in the last quarter. Sowell Financial Services LLC purchased a new stake in shares of ChemoCentryx in the first quarter worth about $28,000. Finally, Swiss National Bank lifted its position in shares of ChemoCentryx by 1.5% in the first quarter. Swiss National Bank now owns 73,500 shares of the biopharmaceutical company’s stock worth $2,953,000 after buying an additional 1,100 shares in the last quarter. Institutional investors own 70.37% of the company’s stock.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy.

Featured Article: Gap Down Stocks

Insider Buying and Selling by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.